Halozyme Therapeutics Inc. (HALO)
Anti-AI Investing: The HALO Moat
I focus on HALO investing: Heavy Assets, Low Obsolescence - owning irreplaceable physical assets with durable moats against technological disruption. Top recommendations include American Tower, Brookfield Infrastructure, Prologis, Rexford Industrial, Lineage, Americold, VICI Properties, and Lamar Advertising. AMT, COLD, and VICI currently offer attractive entry points based on discounted multiples, robust dividend yields, and resilient, monopoly-like asset bases.
Implied Volatility Surging for Halozyme Therapeutics Stock Options
Investors need to pay close attention to HALO stock based on the movements in the options market lately.
Halozyme Therapeutics: Royalty King
Halozyme Therapeutics is delivering strong shareholder value, driven by robust royalty growth and disciplined capital allocation. HALO posted a double beat on Q1 2026 earnings, reaffirmed 2026–2028 guidance, and announced a new $1 billion share repurchase program. HALO trades at a significant discount to historical and sector valuations, despite maintaining >75% gross margins and strong free cash flow.
Halozyme's Q1 Earnings & Revenues Beat Estimates, Stock Up
HALO beats Q1 earnings estimates as royalty revenues from partner drugs and strong product sales lift revenues by 42% year over year.
Halozyme Therapeutics, Inc. (HALO) Q1 2026 Earnings Call Transcript
Halozyme Therapeutics, Inc. (HALO) Q1 2026 Earnings Call Transcript
Halozyme Therapeutics Q1 Earnings Call Highlights
Halozyme Therapeutics NASDAQ: HALO reported a sharp increase in first-quarter 2026 revenue and earnings, driven by continued growth in royalties from its ENHANZE drug-delivery platform, and announced a new $1 billion share repurchase authorization.
Halozyme Therapeutics (HALO) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Halozyme Therapeutics (HALO) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Halozyme Therapeutics (HALO) Surpasses Q1 Earnings and Revenue Estimates
Halozyme Therapeutics (HALO) came out with quarterly earnings of $1.6 per share, beating the Zacks Consensus Estimate of $1.54 per share. This compares to earnings of $1.11 per share a year ago.
Halozyme Therapeutics (HALO) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Besides Wall Street's top-and-bottom-line estimates for Halozyme Therapeutics (HALO), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2026.
Halozyme Therapeutics: The Royalty Engine Is Becoming A Drug-Delivery Toll Road
Halozyme (HALO) is evolving from an ENHANZE royalty story into a diversified subcutaneous drug delivery platform, expanding its technology suite and partner base. FY 2025 royalty revenue surged 52% to $867.8M; 2026 guidance calls for 30–35% royalty growth and adjusted EBITDA of $1.125–$1.205B. Recent acquisitions (Hypercon, Surf Bio) and new partnerships (Vertex, Takeda) extend HALO's IP runway and position it as a one-stop biologic delivery solutions provider.
Halozyme Therapeutics (HALO) Earnings Expected to Grow: What to Know Ahead of Q1 Release
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Goldman's HALO Trade Could Be the 2026 Edge Investors Are Missing
Goldman Sachs (NYSE:GS) has a pretty interesting strategy for investors who aren't yet comfortable braving the dip in some of the hardest-hit stocks, specifically in tech.
